Browsing by Author "Zerdeci N."

Now showing 1 - 2 of 2
  • No Thumbnail Available
    Item
    Our first experience with pascal grid laser photocoagulation in diabetic macular edema; [Diyabetik maküla ödeminde pascal grid lazer fotokoagülasyonu ile ilk tecrübelerimiz]
    (2011) Kayikçioǧlu O.; Seymenoǧlu G.; Zerdeci N.
    Purpose: To assess the efficacy and safety of patterned scan (Pascal) grid laser teratment in diffuse diabetic macular edema. Materials and Methods: Our study included 30 eyes of 25 patients with diffuse macular edema who were never treated before at our institution. All patients had detailed ophthalmologic examination at baseline and at 1, 3 and 6 months after treatment. Best corrected visual acuity (BCVA) was measured using Snellen chart and then converted to logMAR for statistical analysis. Macular thickness (MT) measurements were performed using spectral domain optical cohorence tomography at baseline and at every visit thereafter. Treatment was performed with Pascal system by using its specific grid pattern. Laser parameters and complications were recorded. Results: The mean age of the patients was 57.8±5.6 years. BCVA was 0.63±0.38 (logMAR) at baseline and 0.68±0.47 at 1 month, 0.64±0.47 at 3 months and 0.66±0.47 at 6 months after the treatment. MT was 370±164 μm at baseline and 383±180 μm at 1 month, 374±191 μm at 3 months and 356±196 μm at 6 months after the treatment. There was no statistically significant difference in BCVA and MT before and after the treatment in all visits. There was no complications recorded. Conclusion: Grid photocoagulation by the Pascal system is found to be safe in diffuse diabetic macular edema in short term follow up. BCVA and MT were maintained in all patients at the end of follow up. The efficacy of the treatment seems to be closely related with the metabolic control.
  • No Thumbnail Available
    Item
    Corneal biomechanical properties during the menstrual cycle
    (2011) Seymenoǧlu G.; Baser E.F.; Zerdeci N.; Gülhan C.
    Purpose: To determine if corneal biomechanical properties change during phases of the menstrual cycle. Methods: Twenty-five healthy women of reproductive age with no ocular pathology or systemic diseases were recruited. Corneal hysteresis, corneal resistance factor, Goldman-correlated intraocular pressure, and corneal-compensated intraocular pressure were measured by a Reichert ocular response analyzer at three phases of the menstrual cycle, beginning on days 3 to 5 (follicular phase), again at ovulation (days 14-16, ovulatory phase), and at the end of the cycle (days 25-28, luteal phase). Results: Twenty-one participants completed the study. The mean corneal hysteresis values at follicular, ovulatory, and luteal phases were 10.7, 10.7, and 10.7 mmHg (p>0.05), and the mean corneal resistance factor values at the same time points were 9.9, 9.9, and 9.8 mmHg (p>0.05), respectively. Corneal-compensated intraocular pressure and Goldman-correlated intraocular pressure readings were stable during the course (p>0.05 for all). Conclusions: Corneal biomechanical properties and intraocular pressure as measured by an ocular response analyzer do not change statistically significantly during the different phases of the menstrual cycle. We conclude that measurements of the ocular response analyzer can be safely utilized in healthy female subjects without considering the possible effects of varying hormonal levels during the menstrual cycle. © 2011 Informa Healthcare USA, Inc.